Schouten H C, Maragos D, Vose J, Armitage J O
Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Bone Marrow Transplant. 1990 Nov;6(5):333-5.
We asked in a retrospective analysis whether patients with diabetes mellitus or impaired glucose tolerance are at increased risk for morbidity and mortality after high-dose therapy followed by an autologous bone marrow transplantation. Nine patients with diabetes mellitus (n = 7) or impaired glucose tolerance (n = 2) were identified who had been treated with high-dose therapy and autologous bone marrow transplant for lymphoid malignancies. At the start of the pretransplant conditioning all patients had a Karnofsky score of at least 80 and no clinically demonstrable organ dysfunction. One patient with diabetes mellitus type I (DM I) was transplanted without any complications. The patients with diabetes mellitus type II (DM II) or an impaired glucose tolerance had complications of life-threatening infections (in 6/8), acute renal insufficiency (in 3/8), liver abnormalities with elevated liver enzymes or liver failure (in 4/8) and congestive heart failure (in 1/8). Although the complications observed are not infrequent in the transplant setting, because of the good performance status before BMT and the absence of clinically demonstrable organ impairment before transplantation, it is our impression that the presence of diabetes mellitus or glucose intolerance might be an important co-factor in the morbidity of these patients.
我们在一项回顾性分析中探究,糖尿病或糖耐量受损患者在接受大剂量治疗后进行自体骨髓移植,其发病和死亡风险是否会增加。我们确定了9例患有糖尿病(n = 7)或糖耐量受损(n = 2)的患者,他们因淋巴系统恶性肿瘤接受了大剂量治疗和自体骨髓移植。在移植前预处理开始时,所有患者的卡氏评分至少为80分,且无临床可证实的器官功能障碍。1例I型糖尿病(DM I)患者移植过程无任何并发症。II型糖尿病(DM II)或糖耐量受损的患者出现了危及生命的感染并发症(6/8)、急性肾功能不全(3/8)、伴有肝酶升高的肝脏异常或肝衰竭(4/8)以及充血性心力衰竭(1/8)。尽管在移植过程中观察到的这些并发症并不罕见,但鉴于骨髓移植前患者的身体状况良好且移植前无临床可证实的器官损害,我们认为糖尿病或糖耐量不耐受的存在可能是这些患者发病的一个重要协同因素。